If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
57
results.
Updated on
20/08/2026 [06:45:00]
Results 25 to 50 of 57
Absstract of: US20260226433A1
0000 The present disclosure provides Moloney murine leukemia virus (MMLV) reverse transcriptase (RTase) variants. The present disclosure further provides amino acid positions for mutagenesis of MMLV RTase as well as nucleic acids, kits, compositions, fusion proteins, and methods including MMLV RTase variants.
Absstract of: WO2026162764A1
The present invention relates to improved methods of treating elderly patients newly diagnosed with ALL.
Absstract of: US20260224562A1
0000 Therapeutic methods of treating chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) are described. In certain embodiments, the invention includes therapeutic methods of treating CLL and SLL using a BTK inhibitor. In certain embodiments, the invention includes therapeutic methods of treating subtypes of CLL and SLL using a BTK inhibitor, including subtypes of CLL in patients sensitive to thrombosis and subtypes of CLL that increase monocytes and NK cells in peripheral blood after treatment with a BTK inhibitor. In certain embodiments, the invention includes therapeutic methods of treating CLL and SLL using a combination of a BTK inhibitor and an anti-CD20 antibody.
Absstract of: WO2026028164A1
The present disclosure is directed to methods of treating, for example, newly diagnosed multiple myeloma.
Absstract of: WO2025122791A1
Provided herein are methods and uses for treating multiple myeloma (such as Newly Diagnosed Multiple Myeloma) in a patient in need thereof. The methods comprise administering to the patient an anti-CD38 antibody, bortezomib, lenalidomide, and dexamethasone.
Absstract of: WO2025134050A1
Embodiments of the present disclosure relate to methods of treating multiple myeloma in a subject in need thereof, comprising administering a therapeutically effective amount of a BCMA x GPRC5D x CD3 trispecific antibody or trispecific binding fragment thereof, to the subject to the subject to treat the multiple myeloma.
Absstract of: WO2025122985A1
Provided herein are methods of treating acute myeloid leukemia (AML) in a subject in need thereof, comprising administering to the subject combinations of Compound 1, or a pharmaceutically acceptable salt thereof, venetoclax, and 5-azacitidine. Also provided herein are methods of inhibiting/overcoming resistance of AML to venetoclax in a subject in need thereof, and/or improving the efficacy of venetoclax in the treatment of AML in a subject in need thereof, comprising administering to the subject combinations of Compound 1, or a pharmaceutically acceptable salt thereof, venetoclax, and 5-azacitidine.
Absstract of: WO2026161509A2
The present disclosure provides methods of treating an autoimmune disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a bispecific CD20xCD3 antibody comprising a first antigen-binding arm that specifically binds CD20 and a second antigen-binding arm that specifically binds CDS (e.g., odronextamab or a bioequivalent thereof). In some embodiments, the disclosed methods treat both an autoimmune disorder (e.g., aHUS) and a B-cell cancer (e.g., lymphoma).
Absstract of: US20260216138A1
0000 Provided is a composition for targeting OTUD7B. The composition includes a component sufficient to block or reduce OTUD7B-mediated deubiquitination of GβL in a cell. The component can include 7Bi and variants thereof. Also provided are methods of treating cancer and related conditions, including administering to a cancer patient a OTUD7B catalytic inhibitor, including a 7Bi or variant thereof.
Absstract of: US20260218197A1
The present invention provides a novel secretion reducing agent and novel secretion reducing method for reducing extracellular vesicle secretion from cells. The extracellular vesicle secretion reducing agent of the present invention is characterized in that it contains an inhibitor of a serine synthesis pathway. The cells are, for example, cancer cells such as colorectal cancer cells, lung cancer cells, melanoma cells, breast cancer cells, pancreas cancer cells, and multiple myeloma cells.
Absstract of: AU2025210712A1
Disclosed herein are novel compounds that are Mpsl/TTK inhibitors. Also disclosed herein are compositions comprising the compounds and methods of using the compounds in treating various diseases in a patient. In some embodiments, some such compounds, compositions, and their uses may be useful for the treatment of cancer. In some implementations, the cancer is brain cancer, glioblastoma multiforme, head and neck cancers, colorectal cancer, stomach or gastric cancer, pancreatic cancer, melanoma, bladder cancer, kidney cancer, renal cell carcinoma, breast cancer, ovarian cancer, lymphoma, thyroid cancer, mesothelioma, sarcoma, lung cancer, non-small cell lung cancer, small cell lung cancer, or endometrial cancer.
Absstract of: US20260216204A1
0000 The present disclosure relates to the use of pelabresib, and pharmaceutically acceptable salts and hydrates thereof, for treating lower risk myelodysplastic syndrome (LR-MDS) and conditions associated therewith.
Absstract of: WO2026159094A1
PTLDs arise after solid organ and hematopoietic stem cell transplants, with occurrences linked to immunosuppressive therapy and EBV status. Initial treatment typically involves reducing immunosuppressive therapy and using rituximab, with further options including immunochemotherapy or adoptive cellular therapy for refractory cases. Now, the inventors hypothesized that the concentration of sCD95L could exert a biological function and affect clinical outcomes by modulating the immune response. Using the K-VIROGREF cohort, they dosed by ELISA sCD95L in 175 transplant patients with PTLD and 16 transplant controls. Plasma levels of sCD95L were elevated in transplant recipients. Interestingly, in patients with PTLD who expressed higher concentrations of sCD95L, clinical outcomes were better than those with lower concentrations, especially in patients with central nervous system (CNS) involvement where sCD95L was a marker of good prognostic. Thus, sCD95L is a novel prognostic marker that might guide treatment strategies in patients with PTLD, especially in those with CNS involvement. Therefore, the present invention relates to the use of soluble CD95L as a prognostic marker in post-transplant lymphoproliferative disorders.
Absstract of: US20260218307A1
Described herein are methods for diagnosing and treating mycosis fungoides (MF) and cutaneous T cell lymphoma (CTCL), e.g., for making a differential diagnosis of CTCL/MF versus other skin conditions.
Absstract of: WO2026157435A1
Provided are anti-human CD180 antibodies and the use thereof. The provided anti-human CD180 antibodies A24C9 and C12F11 have high affinity to human CD180 protein, with Kd values thereof being 0.4748 nM and 78.19 nM respectively; said antibodies have high binding specificity and can specifically recognize human CD180-positive acute myeloid leukemia (AML) cell lines (OCI-AML2, MV4-11, THP1) and human CD180-positive B-cell lymphoma cell lines (Daudi, BJAB, Nalm6), and have no cross-reactivity with various human CD180-negative cell lines (K562, NB4, Kasumi1, TF1, NK92, Jurkat, SupT1 and MM1S). Said antibodies can be used not only for detecting the expression of human CD180 protein, but also for immunotherapy alone or in combination with other methods, and have diagnostic and therapeutic values for tumors, autoimmune diseases, graft-versus-host diseases and inflammatory diseases.
Absstract of: WO2026157434A1
Provided are a CD180-targeting chimeric antigen receptor and the use thereof. By means of flow cytometry, degranulation assays and assays of cytokines secreted by T cells, it is proved that T cells modified with the chimeric antigen receptor have potent killing effect on acute myeloid leukemia cells that express CD180, and have no killing effect on cells that do not express CD180, effectively preventing off-target effect; and the colony formation ability of umbilical cord blood-derived CD34+ hematopoietic stem/progenitor cells is not affected, achieving safety. The chimeric antigen receptor CD180 scFv-CD8α-4-1BB-CD3ζ can be used for the treatment of CD180-positive hematological tumors.
Absstract of: US20260217788A1
Provided herein is a method of treating a subject who has a cancer. At least one dose of chimeric antigen receptor (CAR)-T cells comprising a CAR comprising a polypeptide is administered to the subject. The peptide comprises an extracellular antigen binding domain with at least two BCMA-binding moieties, a transmembrane domain, and an intracellular signaling domain. The dose of CAR-T cells administered to the subject is from 4.0×105 to 1.0×106 of CAR-T cells per kilogram of the subject's mass. Alternatively, the dose comprises 1×106 to 1×108 of the CAR-T cells.
Absstract of: US20260216327A1
0000 Provided are adoptive cell therapy involving the administration of doses of cells for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is a large B cell lymphoma, such as a diffuse large B-cell lymphoma (DLBCL). Also provided are methods of assessing the risk of developing a toxicity related to a cell therapy, and methods of identifying subjects and methods of treating subjects based on the assessment of risks.
Absstract of: US20260217723A1
0000 Some embodiments of the disclosure include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the inventive IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.
Absstract of: EP4782436A2
Disclosed herein are compounds, 6-substituted-2-(1,1'-biphenyl-4-yl)quinoline-4-carboxylic acid analogs, that are inhibitors of dihydroorotate dehydrogenase (DHODH) with improved pharmacokinetic properties. The disclosed compounds can be used in the treatment of a variety of disorders and diseases in which inhibition of DHODH can be clinically useful, including cancer, such as a hematological cancer, including acute myeloid leukemia (AML); graft-versus-host-diseases; autoimmune disorders; and disorders associated with T-cell proliferation. The disclosed compounds can demonstrate flip-flop kinetics when administered orally, i.e., pharmacokinetics in which the rate of absorption, rather than the rate of elimination, dominates the pharmacokinetics. The disclosed compounds can demonstrate a sustained pharmacokinetic profile instead of an immediate release profile. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
Absstract of: EP4782010A1
0001 The use of an anti-CD20 antibody-drug conjugate or a pharmaceutical combination thereof in the preparation of a drug for treating non-Hodgkin lymphoma. The pharmaceutical combination comprises the anti-CD20 antibody-drug conjugate and at least one therapeutic agent. Compared with existing clinical second-line standard therapies, combination therapy using the anti-CD20 antibody-drug conjugate or the pharmaceutical combination comprising same has a better therapeutic effect.
Absstract of: US20260207742A1
0000 Provided is a pharmaceutical combination comprising an antibody specific for CD19 and a natural killer cell, and a treatment method using the same. Such a pharmaceutical combination is capable of exhibiting synergistic therapeutic effects on a malignant tumor of B-cell origin such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and/or acute lymphoblastic leukemia.
Absstract of: US20260207757A1
0000 Provided are methods of treating myelodysplastic syndrome (MDS), oligoblastic acute myelogenous leukemia (O-AML), or chronic myelomonocytic leukemia (CMML) using 765IGF-MTX and other IGF-receptor-targeted agents, and formulations for delivering 765IGF-MTX and other IGF-receptor-targeted agents to patients. Also provided are pharmaceutical compositions for use in treating MDS, O-AML, and CMML.
Absstract of: US20260209271A1
Disclosed herein is a series of helical sulfono-γ-AApeptides that mimic the binding mode of the α-helical HD2 domain of B-Cell Lymphoma 9 (BCL9). As disclosed herein, sulfono-γ-AApeptides can structurally and functionally mimic the α-helical domain of BCL9, and selectively disrupt β-catenin/BCL9 PPIs with even higher potency. More intriguingly, these sulfono-γ-AApeptides can enter cancer cells, bind with β-catenin and disrupt β-catenin/BCL PPI, and exhibit excellent cellular activity, which is much more potent than the BCL9 peptide. Furthermore, enzymatic stability studies demonstrated the remarkable stability of the helical sulfono-γ-AApeptides, with no degradation in the presence of pronase for 24 h, augmenting their biological potential.
Nº publicación: US20260207557A1 23/07/2026
Applicant:
LOXO ONCOLOGY INC [US]
Loxo Oncology, Inc.
Absstract of: US20260207557A1
This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
BOPI
Electronic site
